查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1726215

前列腺癌生物标记市场规模、份额、趋势分析报告：按类型、应用、最终用途、地区和细分市场预测，2025 年至 2030 年

Prostate Cancer Biomarkers Market Size, Share & Trends Analysis Report By Type (Genetic Biomarkers, Cell-based Biomarkers, Metabolomic Biomarkers), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

前列腺癌生物标记市场的成长和趋势

根据 Grand View Research, Inc. 的新报告，全球前列腺癌生物标记市场规模预计到 2030 年将达到 98 亿美元，2025-2030 年期间的复合年增长率为 13.1%。

由于对精准诊断的需求不断增加以及 PSA 测试等传统筛检方法的局限性，市场正在快速发展。儘管PSA检测被广泛使用，但其特异性较低，并且经常导致过度诊断和过度治疗。因此，人们明显转向使用分子和基因生物标誌物来提高诊断准确性并指南临床决策。 PCA3（前列腺癌抗原 3）、4Kscore 和 ConfirmMDx 等新兴生物标记在风险分层和切片检查决策支持方面表现出色。这些测试越来越多地被纳入临床实践中，以减少不必要的切片检查并改善患者的治疗效果。

一个主要的市场驱动力是对个人化医疗的日益关注。 Decipher GPS 和 Oncotype DX GPS 等基因组分类方法可以帮助前列腺肿瘤进行分级并为治疗计划提供资讯。液态切片技术也因其非侵入性而受到关注，基于尿液的测试（例如 SelectMDx 和 ExoDx）为 PSA 升高的患者提供了可进行临床操作的见解。当传统切片检查存在风险或结果不确定时，这些创新尤其重要。

次世代定序仪(NGS) 和转录组学的技术进步正在进一步加速生物标记的发现。例如，研究已将TMPRSS2-ERG等基因融合以及BRCA1/2和ATM的突变确定为预后和治疗指南的重要标记。这些生物标记在选择接受 PARP 抑制剂等标靶治疗的患者时的应用日益广泛，反映了伴随诊断在治疗生态系中日益增长的重要性。此外，分析与肿瘤进展相关的小分子代谢变化的代谢组学生物标记正在成为早期检测和监测的有希望的工具。

然而，市场仍面临一些挑战。生物标记检测的标准化仍然有限，临床医生对于在哪个临床阶段应该采用哪些检测尚未达成共识。报销问题和成本问题可能会阻碍先进生物标记测试的常规使用，尤其是在医疗预算受限的地区。此外，生物标誌物的核准流程通常很长，可能会延迟商业化。即使市场上出现了较新的测试，广泛的临床应用也需要大量的检验研究和与现有临床工作流程的整合。

儘管存在这些障碍，前列腺癌生物标记行业仍存在显着的成长机会。学术界和工业界之间的合作正在加速，以发现和检验新的生物标记组。随着人们越来越意识到 PSA 检测的局限性以及对价值导向医学的重视，人们越来越倾向于采用更具资讯量、侵入性更小的诊断方法。在此背景下，用于监测晚期前列腺癌抗治疗性的AR-V7 等生物标记为生物标记指导治疗选择提供了潜力。

随着这一领域的不断发展，前列腺癌诊断正在朝着更全面和个人化的模式发展，其中分子见解不仅可以指导早期检测，还可以指导治疗方法决策和长期管理策略。

市场的主要参与企业包括 Exact Sciences、Myriad Genetics、Bio-Techne、Olympus Corporation 和 OPKO Health。这些公司正在采取各种策略性倡议，包括产品发布和核准，以服务其全球客户。例如，2024 年 12 月，Myriad Genetics 的 Prolaris 测试继续获得美国国家综合癌症网络 (NCCN) 的核准，成为前列腺癌预后的高级工具。它继续被纳入 NCCN 指南，其 2A 类证据等级表明其获得了 NCCN 前列腺专家组的大力支持 (>=85%)。这种分类加强了 Prolaris 的临床相关性，有助于根据肿瘤侵袭性指导治疗决策。

前列腺癌生物标记市场报告重点

  • 根据类型，蛋白质生物标记在 2024 年占据了最大的收入份额，为 57.73%。前列腺癌生物标记市场中的蛋白质生物标记部分受到 PSA 和 PHI 测试的广泛临床应用、前列腺癌发病率的上升以及对临床指南的大力支持的推动。多重检测和 4Kscore 等风险分层工具的技术进步正在提高诊断的准确性。此外，对非侵入性和经济高效的就地检验方案的需求不断增长，正在推动这一领域在已开发市场和新兴市场的进一步成长。
  • 筛检和早期检测将占据市场主导地位，到 2024 年将占据 45.14% 的最大份额。筛检和早期检测市场的发展受到疾病盛行率上升、人口老化和非侵入性检测的采用的推动。例如，PSA 检测仍然是全球标准，而前列腺健康指数 (PHI) 和 4Kscore 提高了特异性并减少了不必要的切片检查。美国预防服务工作组 (USPSTF) 建议 55 至 69 岁的男性进行 PSA 检测等项目进一步推动了需求。社会意识的增强和诊断服务的改善也支持了这一领域的成长。
  • 医院和诊断实验室是前列腺癌生物标记行业的主要推动者，因为它们在患者诊断、切片检查评估和治疗计划中发挥核心作用。患者数量的增加、先进诊断基础设施的可用性以及对 PSA、PHI 和 ConfirmMDx 等准确的早期检测测试的需求正在推动市场成长。此外，将生物标记检测整合到常规泌尿系统工作流程和医院癌症筛检计画中，将进一步推动已开发地区和新兴地区对此检测的采用和发展。
  • 北美凭藉其先进的诊断能力、精准医疗的早期采用以及支持性的法规结构，在前列腺癌生物标记市场占据主导地位。基于生物标记的测试，例如 ExoDx Prostate（来自 Bio-Techne 的基于尿液的外泌体 RNA 测试）和 SelectMDx（来自 MDxHealth 的 mRNA 测试）被广泛用于指导切片检查决策。此外，美国国家综合癌症网络 (NCCN) 临床指南建议使用生物标记。基因组学投资的增加以及学术中心和生物技术公司之间的合作继续推动全部区域的创新和生物标誌物的采用。
  • 预计 2025-2030 年预测期内亚太地区成长最快，复合年增长率为 14.4%。这是由于中国、印度和日本等国家对癌症意识的不断提高、医疗保健基础设施的改善以及医疗保健支出的增加。扩大 PSA 筛检、PHI 和 4Kscore 等新检测的覆盖范围正在推动早期检测。地方政府正在推出全国癌症筛检倡议，对精准医疗和分子诊断的投资不断增加，推动生物标记的采用。当地医院和生物技术公司的合作进一步支持了创新和市场扩张。

目录

第一章调查方法与范围

第二章执行摘要

3. 前列腺癌生物标记市场变数、趋势和范围

  • 前列腺癌生物标记市场的系统性概述
    • 母市场展望
  • 渗透和成长前景图
  • 管道分析
    • 筛检和早期检测
    • 诊断和风险分层
    • 预后和治疗监测
    • 伴随诊断
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 前列腺癌生物标记：市场分析工具
    • 产业分析—波特五力分析
    • PESTLE分析

4. 前列腺癌生物标记市场：細項分析（按类型），2018-2030

  • 前列腺癌生物标记市场：类型变异分析

5. 前列腺癌生物标记市场：細項分析、应用分析，2018-2030

  • 前列腺癌生物标记市场：应用变异分析

6. 前列腺癌生物标记市场：細項分析、依最终用途，2018-2030 年

  • 前列腺癌生物标记市场：最终用途变异分析

7. 前列腺癌生物标记市场：区域細項分析，2018-2030

  • 区域市场概况
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

8.前列腺癌生物标记市场竞争分析

  • 公司分类
  • 战略地图
    • 新产品发布
    • 伙伴关係
    • 获得
    • 合作
    • 资金筹措
  • 2022年公司市场占有率分析
  • 公司简介
    • EXACT SCIENCES CORPORATION
    • MYRIAD GENETICS, INC.
    • BIO-TECHNE
    • EXODX
    • OPKO HEALTH,INC.
    • MDXHEALTH
    • VERACYTE, INC.
    • BECKMAN COULTER, INC.
    • NUCLEIX
    • DIACARTA
Product Code: GVR-4-68040-547-6

Prostate Cancer Biomarkers Market Growth & Trends:

The global prostate cancer biomarkers market size is expected to reach USD 9.8 billion by 2030, registering a CAGR of 13.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is undergoing rapid evolution driven by the increasing demand for precision diagnostics and the limitations of conventional screening methods like PSA testing. PSA, while widely used, has low specificity, often leading to overdiagnosis and overtreatment. As a result, there is a significant shift towards molecular and genomic biomarkers that can offer improved diagnostic accuracy and guide clinical decisions. Emerging biomarkers such as PCA3 (Prostate Cancer Antigen 3), 4Kscore, and ConfirmMDx have demonstrated superior performance in risk stratification and biopsy decision support. These tests are increasingly being integrated into clinical practice to reduce unnecessary biopsies and improve patient outcomes.

A key market driver is the growing focus on personalized medicine. Genomic classifiers like Decipher and Oncotype DX GPS help determine the aggressiveness of prostate tumors and inform treatment planning, especially in early-stage patients deciding between active surveillance and intervention. Liquid biopsy-based technologies are also gaining attention for their non-invasive nature, with urine-based tests like SelectMDx and ExoDx offering clinically actionable insights for patients with elevated PSA. These innovations are particularly relevant in cases where traditional biopsies carry risks or yield inconclusive results.

Technological advancements in next-generation sequencing (NGS) and transcriptomics are further accelerating biomarker discovery. For example, studies have identified gene fusions such as TMPRSS2-ERG and mutations in BRCA1/2 and ATM as significant markers for prognosis and therapeutic guidance. The increasing use of these biomarkers in selecting patients for targeted therapies like PARP inhibitors reflects the rising importance of companion diagnostics in the treatment ecosystem. Moreover, metabolomic biomarkers, which analyze small-molecule metabolic changes associated with tumor progression, are emerging as promising tools for early detection and monitoring.

However, the market still faces several challenges. Standardization across biomarker assays remains limited, and there is a lack of consensus among clinicians regarding which tests to adopt and at what clinical stages. Reimbursement issues and cost concerns can hinder the routine use of advanced biomarker tests, particularly in regions with constrained healthcare budgets. Furthermore, regulatory pathways for biomarker approval are often lengthy, which can delay commercial availability. Even as newer tests enter the market, widespread clinical adoption requires large-scale validation studies and integration into existing clinical workflows.

Despite these barriers, the prostate cancer biomarker industry presents notable growth opportunities. Collaborations between academia and industry are intensifying, aimed at discovering and validating novel biomarker panels. With increasing awareness of the limitations of PSA and growing emphasis on value-based care, there is strong momentum to shift toward more informative, less invasive diagnostics. In this context, biomarkers like AR-V7, used for monitoring treatment resistance in advanced prostate cancer, illustrate the potential of biomarker-guided therapy selection.

As the field continues to advance, prostate cancer diagnostics are moving toward a more integrated and individualized model, where molecular insights guide not only early detection but also therapeutic decisions and long-term management strategies.

Some of the key players in the market are Exact Sciences, Myriad Genetics, Bio-Techne, Olympus Corporation, OPKO Health. These players are involved in various strategic initiatives such as product launch and approval in order to cater to a global clientele. For instance, in December 2024, Myriad Genetics' Prolaris test continues to be recognized by the National Comprehensive Cancer Network (NCCN) as an Advanced Tool for prostate cancer prognosis. It remains included in the NCCN guidelines with a Category 2A evidence level, indicating strong support (>=85%) from the NCCN prostate panel. This classification reinforces Prolaris' clinical relevance in helping guide treatment decisions based on tumor aggressiveness.

Prostate Cancer Biomarker Market Report Highlights:

  • Based on type, protein biomarkersaccounted for largest revenue share of 57.73% in 2024. The protein biomarkers segment in the prostate cancer biomarkers market is driven by the widespread clinical use of PSA and PHI tests, rising prostate cancer prevalence, and strong clinical guideline support. Technological advances in multiplex assays and risk stratification tools like the 4Kscore enhance diagnostic accuracy. Additionally, increased demand for non-invasive, cost-effective, and point-of-care testing solutions fuels further growth in this segment across both developed and emerging markets.
  • Based on application screening and early detection dominated the market and accounted for the largest share of 45.14% in 2024.The screening and early detection segment in the market is driven by rising disease prevalence, aging populations, and adoption of non-invasive tests. For example, PSA testing remains a global standard, while PHI (Prostate Health Index) and the 4Kscore offer improved specificity, reducing unnecessary biopsies. Programs like the U.S. Preventive Services Task Force (USPSTF) recommendation for PSA testing in men aged 55-69 further boost demand. Increased public awareness and improved access to diagnostic services also support growth in this segment.
  • Based on end use, hospitals and diagnostic laboratories segment dominated the market and accounted for the largest share of 63.24% in 2024.Hospitals and diagnostic laboratories are key drivers in the prostate cancer biomarker industry due to their central role in patient diagnosis, biopsy evaluation, and treatment planning. Increasing patient volumes, availability of advanced diagnostic infrastructure, and demand for accurate, early-stage detection tests like PSA, PHI, and ConfirmMDx fuel market growth. Additionally, integration of biomarker testing into routine urology workflows and hospital-based cancer screening programs further enhances test adoption and market expansion in both developed and emerging regions.
  • North America dominates the prostate cancer biomarkers market due to advanced diagnostic capabilities, early adoption of precision medicine, and supportive regulatory frameworks. Biomarker-based tests such as ExoDx Prostate (urine-based exosomal RNA test by Bio-Techne) and SelectMDx (mRNA test by MDxHealth) are widely utilized for biopsy decision-making. Additionally, clinical guidelines from the National Comprehensive Cancer Network (NCCN) endorse biomarker usage. Growing investment in genomics and partnerships between academic centers and biotech firms continue to drive innovation and biomarker adoption across the region.
  • Asia Pacific region is expected to witness fastest growth with a CAGR of 14.4% over the forecast period from 2025 to 2030, due to increasing cancer awareness, improving healthcare infrastructure, and rising healthcare expenditure in countries like China, India, and Japan. Expanding access to PSA screening and newer tests such as PHI and 4Kscore is driving early detection. Local governments are launching national cancer screening initiatives, and growing investments in precision medicine and molecular diagnostics are boosting biomarker adoption. Collaborations between regional hospitals and biotech firms are further fueling innovation and market expansion.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Definition
      • 1.1.1.1 Application Segment
      • 1.1.1.2 Type Segment
      • 1.1.1.3 End Use Segment
  • 1.2 Regional Scope
  • 1.3 Estimates and Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 Gvr's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List of Secondary Sources
  • 1.11 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Application and Type Snapshot
  • 2.3 End Use Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 Prostate Cancer Biomarkers Market Variables, Trends, and Scope

  • 3.1 Prostate Cancer Biomarkers Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
  • 3.2 Penetration and Growth Prospect Mapping
  • 3.3 Pipeline Analysis
    • 3.3.1 Screening And Early Detection
    • 3.3.2 Diagnosis And Risk Stratification
    • 3.3.3 Prognosis And Treatment Monitoring
    • 3.3.4 Companion Diagnostics
  • 3.4 Market Dynamics
    • 3.4.1 Market Driver Analysis
      • 3.4.1.1 Rising prevalence of prostate cancer
      • 3.4.1.2 Advancements in Genomic and Proteomic Technologies
      • 3.4.1.3 Supportive Government and Research Initiatives
    • 3.4.2 Market Restraint Analysis
      • 3.4.2.1 High Cost of Biomarker-Based Tests
      • 3.4.2.2 Uneven Access to Advanced Diagnostic Infrastructure
  • 3.5 Prostate Cancer Biomarkers: Market Analysis Tools
    • 3.5.1 Industry Analysis - Porter's
    • 3.5.2 Pestle Analysis

Chapter 4 Prostate Cancer Biomarkers Market: Segment Analysis, By Type, 2018 - 2030 (USD Million)

  • 4.1 Prostate Cancer Biomarkers Market: Type Movement Analysis
    • 4.1.1 Genetic Biomarkers
      • 4.1.1.1 Genetic Biomarkers Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.2 Protein Biomarkers
      • 4.1.2.1 Protein Biomarkers Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.3 Cell-Based Biomarkers
      • 4.1.3.1 Cell-Based Biomarkers Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.5 Metabolomic Biomarkers
      • 4.1.5.1 Metabolomic Biomarkers Prostate Cancer Biomarkers Market, 2018 - 2030, USD Million

Chapter 5 Prostate Cancer Biomarkers Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

  • 5.1 Prostate Cancer Biomarkers Market: Application Movement Analysis
    • 5.1.1 Screening And Early Detection
      • 5.1.1.1 Screening And Early Detection Market, 2018 - 2030 (USD Million)
    • 5.1.2 Diagnosis And Risk Stratification
      • 5.1.2.1 Diagnosis And Risk Stratification Market, 2018 - 2030 (USD Million)
    • 5.1.3 Prognosis And Treatment Monitoring
    • 5.3.1 Prognosis And Treatment Monitoring Market, 2018 - 2030 (USD Million)
    • 5.1.4 Companion Diagnostics
      • 5.1.4.1 Companion Diagnostics Market, 2018 - 2030 (USD Million)

Chapter 6 Prostate Cancer Biomarkers Market: Segment Analysis, By End Use, 2018 - 2030 (USD Million)

  • 6.1 Prostate Cancer Biomarkers Market: End Use Movement Analysis
    • 6.1.1 Hospitals And Diagnostic Laboratories
      • 6.1.1.1 Hospitals And Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
    • 6.1.2 Academic And Research Institutes
      • 6.1.2.1 Academic And Research Institutes Market, 2018 - 2030 (USD Million)
    • 6.1.3 Biopharmaceutical Companies
      • 6.1.3.1 Biopharmaceutical Companies Market, 2018 - 2030 (USD Million)

Chapter 7 Prostate Cancer Biomarkers Market: Segment Analysis, By Region, 2018 - 2030 (USD Million)

  • 7.1 Regional Market Snapshot
  • 7.2 North America
    • 7.2.1 North America Prostate Cancer Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.2.2.2 Key Country Dynamics
      • 7.2.2.3 Regulatory Framework
      • 7.2.2.4 Reimbursement Scenario
    • 7.2.3 Canada
      • 7.2.3.1 Canada Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.2.3.2 Key Country Dynamics
      • 7.2.3.3 Regulatory Framework
      • 7.2.3.4 Reimbursement Scenario
    • 7.2.4 Mexico
      • 7.2.4.1 Mexico Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.2.4.2 Key Country Dynamics
      • 7.2.4.3 Regulatory Framework
      • 7.2.4.4 Reimbursement Scenario
  • 7.3 Europe
    • 7.3.1 Europe Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.2 UK
      • 7.3.2.1 UK Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.2.2 Key Country Dynamics
      • 7.3.2.3 Regulatory Framework
      • 7.3.2.4 Reimbursement Scenario
    • 7.3.3 Germany
      • 7.3.3.1 Germany Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.3.2 Key Country Dynamics
      • 7.3.3.3 Regulatory Framework
      • 7.3.3.4 Reimbursement Scenario
    • 7.3.4 Spain
      • 7.3.4.1 Spain Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.4.2 Key Country Dynamics
      • 7.3.4.3 Regulatory Framework
      • 7.3.4.4 Reimbursement Scenario
    • 7.3.5 France
      • 7.3.5.1 France Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.5.2 Key Country Dynamics
      • 7.3.5.3 Regulatory Framework
      • 7.3.5.4 Reimbursement Scenario
    • 7.3.6 Italy
      • 7.3.6.1 Italy Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.6.2 Key Country Dynamics
      • 7.3.6.3 Regulatory Framework
      • 7.3.6.4 Reimbursement Scenario
    • 7.3.7 Denmark
      • 7.3.7.1 Denmark Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.7.2 Key Country Dynamics
      • 7.3.7.3 Regulatory Framework
      • 7.3.7.4 Reimbursement Scenario
    • 7.3.8 Sweden
      • 7.3.8.1 Sweden Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.8.2 Key Country Dynamics
      • 7.3.8.3 Regulatory Framework
      • 7.3.8.4 Reimbursement Scenario
    • 7.3.9 Norway
      • 7.3.9.1 Norway Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.9.2 Key Country Dynamics
      • 7.3.9.3 Regulatory Framework
      • 7.3.9.4 Reimbursement Scenario
  • 7.4 Asia Pacific
    • 7.4.1 Asia-Pacific Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.2 Japan
      • 7.4.2.1 Japan Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.2.2 Key Country Dynamics
      • 7.4.2.3 Regulatory Framework
      • 7.4.2.4 Reimbursement Scenario
    • 7.4.3 China
      • 7.4.3.1 China Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.3.2 Key Country Dynamics
      • 7.4.3.3 Regulatory Framework
      • 7.4.3.4 Reimbursement Scenario
    • 7.4.4 India
      • 7.4.4.1 India Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.4.2 Key Country Dynamics
      • 7.4.4.3 Regulatory Framework
      • 7.4.4.4 Reimbursement Scenario
    • 7.4.5 South Korea
      • 7.4.5.1 South Korea Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.5.2 Key Country Dynamics
      • 7.4.5.3 Regulatory Framework
      • 7.4.5.4 Reimbursement Scenario
    • 7.4.6 Thailand
      • 7.4.6.1 Thailand Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.6.2 Key Country Dynamics
      • 7.4.6.3 Regulatory Framework
      • 7.4.6.4 Reimbursement Scenario
    • 7.4.7 Australia
      • 7.4.7.1 Australia Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.7.2 Key Country Dynamics
      • 7.4.7.3 Regulatory Framework
      • 7.4.7.4 Reimbursement Scenario
  • 7.5 Latin America
    • 7.5.1 Latin America Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.5.2.2 Key Country Dynamics
      • 7.5.2.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
    • 7.5.3 Argentina
      • 7.5.3.1 Argentina Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.5.3.2 Key Country Dynamics
      • 7.5.3.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
  • 7.6 MEA
    • 7.6.1 MEA Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.2.2 Key Country Dynamics
      • 7.6.2.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.3.2 Key Country Dynamics
      • 7.6.3.3 Regulatory Framework
      • 7.6.3.4 Reimbursement Scenario
    • 7.6.4 UAE
      • 7.6.4.1 UAE Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.4.2 Key Country Dynamics
      • 7.6.4.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.5 Kuwait
      • 7.6.5.1 Kuwait Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.5.2 Key Country Dynamics
      • 7.6.5.3 Regulatory Framework
      • 7.6.5.4 Reimbursement Scenario

Chapter 8 Prostate Cancer Biomarkers Market: Competitive Analysis

  • 8.1 Company Categorization
  • 8.2 Strategy Mapping
    • 8.2.1 New product launch
    • 8.2.2 Partnerships
    • 8.2.3 Acquisition
    • 8.2.4 Collaboration
    • 8.2.5 Funding
  • 8.3 Company Market Share Analysis, 2022
  • 8.4 Company Profiles
    • 8.4.1 EXACT SCIENCES CORPORATION
      • 8.4.1.1 Company overview
      • 8.4.1.2 Financial performance
      • 8.4.1.3 Product benchmarking
      • 8.4.1.4 Strategic initiatives
    • 8.4.2 MYRIAD GENETICS, INC.
      • 8.4.2.1 Company overview
      • 8.4.2.2 Financial performance
      • 8.4.2.3 Product benchmarking
      • 8.4.2.4 Strategic initiatives
    • 8.4.3 BIO-TECHNE
      • 8.4.3.1 Company overview
      • 8.4.3.2 Financial performance
      • 8.4.3.3 Product benchmarking
      • 8.4.3.4 Strategic initiatives
    • 8.4.4 EXODX
      • 8.4.4.1 Company overview
      • 8.4.4.2 Product benchmarking
      • 8.4.4.3 Product benchmarking
      • 8.4.4.4 Strategic initiatives
    • 8.4.5 OPKO HEALTH,INC.
      • 8.4.5.1 Company overview
      • 8.4.5.2 Product benchmarking
      • 8.4.5.3 Strategic initiatives
    • 8.4.6 MDXHEALTH
      • 8.4.6.1 Company overview
      • 8.4.6.2 Financial performance
      • 8.4.6.3 Product benchmarking
      • 8.4.6.4 Strategic initiatives
    • 8.4.7 VERACYTE, INC.
      • 8.4.7.1 Company overview
      • 8.4.7.2 Financial performance
      • 8.4.7.3 Product benchmarking
      • 8.4.7.4 Strategic initiatives
    • 8.4.8 BECKMAN COULTER, INC.
      • 8.4.8.1 Company overview
      • 8.4.8.2 Product benchmarking
    • 8.4.9 NUCLEIX
      • 8.4.9.1 Company overview
      • 8.4.9.2 Financial performance
      • 8.4.9.3 Product benchmarking
      • 8.4.9.4 Strategic initiatives
    • 8.4.10 DIACARTA
      • 8.4.10.1 Company overview
      • 8.4.10.2 Product benchmarking
      • 8.4.10.3 Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 3 North America Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 5 U.S. Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 7 U.S. Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 8 Canada Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 9 Canada Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 10 Canada Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Mexico Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 12 Mexico Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 13 Mexico Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 12 Europe Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 13 Europe Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 14 U.K. Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 15 U.K. Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 16 U.K. Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 17 Germany Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 18 Germany Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 19 Germany Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 20 France Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 21 France Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 22 France Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 23 Italy Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 24 Italy Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 25 Italy Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Spain Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 27 Spain Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 28 Spain Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 29 Denmark Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 30 Denmark Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 31 Denmark Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 32 Sweden Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 33 Sweden Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 34 Sweden Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 35 Norway Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 36 Norway Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 37 Norway Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 38 Asia Pacific Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Japan Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 42 Japan Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 43 Japan Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 44 China Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 45 China Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 46 China Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 47 India Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 48 India Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 49 India Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 50 South Korea Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 51 South Korea Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 52 South Korea Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 53 Australia Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 54 Australia Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 55 Australia Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Thailand Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 57 Thailand Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 58 Thailand Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Latin America Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 60 Latin America Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 61 Latin America Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Brazil Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 63 Brazil Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 64 Brazil Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 68 Argentina Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 69 Argentina Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 70 Argentina Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 71 MEA Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 72 MEA Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 73 MEA Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 74 South Africa Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 75 South Africa Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 76 South Africa Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 77 Saudi Arabia Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 78 Saudi Arabia Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 79 Saudi Arabia Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 80 UAE Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 81 UAE Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 82 UAE Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 83 Kuwait Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 84 Kuwait Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 85 Kuwait Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Prostate Cancer Biomarkers market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot (Type and application)
  • Fig. 11 Segment snapshot (End Use)
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Biomarkers market value, 2024 (USD Million)
  • Fig. 14 Prostate Cancer Biomarkers market dynamics
  • Fig. 15 Prevalence of Screening and Early Detection by age group, 2024
  • Fig. 16 Prostate Cancer Biomarkers market: PORTER's analysis
  • Fig. 17 Prostate Cancer Biomarkers market: PESTLE analysis
  • Fig. 18 Prostate Cancer Biomarkers market: Type outlook and key takeaways
  • Fig. 19 Prostate Cancer Biomarkers market: Type movement analysis
  • Fig. 20 Genetic Biomarkers Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Protein Biomarkers Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Cell-based Biomarkers Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Metabolomic Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Prostate Cancer Biomarkers market: Application outlook and key takeaways
  • Fig. 26 Prostate Cancer Biomarkers market: Application movement analysis
  • Fig. 27 Screening and Early Detection market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Diagnosis and Risk Stratification market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Prognosis and Treatment Monitoring market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Companion Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Prostate Cancer Biomarkers market: End Use outlook and key takeaways
  • Fig. 33 Prostate Cancer Biomarkers market: End Use movement analysis
  • Fig. 34 Hospitals and Diagnostic Laboratories market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Academic and Research Institutes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Biopharmaceutical Companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Prostate Cancer Biomarkers market revenue, by region, 2022 & 2030, (USD Million)
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 U.S. Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Target disease prevalence
  • Fig. 44 Key country dynamics
  • Fig. 45 Canada Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Target disease prevalence
  • Fig. 47 Europe Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 UK Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Germany Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Target disease prevalence
  • Fig. 53 Key country dynamics
  • Fig. 54 France Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Italy Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Spain Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Denmark Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Sweden Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Norway Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 Target disease prevalence
  • Fig. 66 Rest of Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Japan Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Target disease prevalence
  • Fig. 71 Key country dynamics
  • Fig. 72 China Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 India Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Target disease prevalence
  • Fig. 76 Key country dynamics
  • Fig. 77 Australia Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Thailand Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 South Korea Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Rest of Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Latin America Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Brazil Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Mexico Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Argentina Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Rest of Latin America Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 MEA Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 South Africa Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Target disease prevalence
  • Fig. 95 Key country dynamics
  • Fig. 96 Saudi Arabia Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Target disease prevalence
  • Fig. 98 Key country dynamics
  • Fig. 99 UAE Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Target disease prevalence
  • Fig. 101 Key country dynamics
  • Fig. 102 Kuwait Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Target disease prevalence
  • Fig. 104 Key payors in Kuwait
  • Fig. 105 Rest of MEA Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Key company categorization
  • Fig. 107 Company market positioning
  • Fig. 108 Company market share analysis, 2022
  • Fig. 109 Strategic framework